Overall survival and fungal infection-related mortality in patients with invasive fungal infection and neutropenia after myelosuppressive chemotherapy in a tertiary care centre from 1995 to 2006

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 4, 2010, Pages 761-768

  Hahn Ast, Corinna ^a   Glasmacher, Axel ^a   Mückter, Sara ^a   Schmitz, Andrea ^a   Kraemer, Anja ^a   Marklein, Günter ^a   Brossart, Peter ^a   von Lilienfeld Toal, Marie ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Acute leukaemia; Antifungal agents; Outcomes research; Prognostic factors

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; COLISTIN; COTRIMOXAZOLE; CYTARABINE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; VORICONAZOLE; ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; ASPERGILLUS; CANDIDA ALBICANS; CHEMOTHERAPY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIPODASCUS CAPITATUS; DISEASE DURATION; DRUG MEGADOSE; FEMALE; HAZARD RATIO; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUCOR; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; QUESTIONNAIRE; SYSTEMIC MYCOSIS; TERTIARY HEALTH CARE; TREATMENT RESPONSE; BLOOD DISEASE; CHEMICALLY INDUCED DISORDER; DRUG THERAPY; IMMUNOCOMPROMISED PATIENT; MIDDLE AGED; MYCOSIS; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG THERAPY; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; MYCOSES; NEUTROPENIA; QUESTIONNAIRES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77952561474     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp507     Document Type: Article

References (31)

1. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002; 81: 233-43.
2. Pagano L, Caira M, Candoni A et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91: 1068-75.
3. Böhme A, Ruhnke M, Buchheidt D et al. Treatment of invasive fungal infections in cancer patients. Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009; 88: 97-110.
4. Marr KA, Carter RA, Crippa F et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909-17.
5. Mühlemann K, Wenger C, Zenhäusern R et al. Risk factors for invasive aspergillosis in neutropenic patients with hematologic malignancies. Leukemia 2005; 19: 545-50.
6. Cuenca-Estrella M, Bernal-Martinez L, Buitrago MJ et al. Update on the epidemiology and diagnosis of invasive fungal infection. Int J Antimicrob Agents 2008; 32 Suppl 2: S143-7.
7. Auberger J, Lass-Flörl C, Ulmer H et al. Significant alterations in the epidemiology and treatment outcome of invasive fungal infections in patients with hematological malignancies. Int J Hematol 2008; 88: 508-15.
8. Donhuijsen K, Petersen P, Schmid KW. Trend reversal in the frequency of mycoses in hematological neoplasias. Dtsch Ärztebl Int 2008; 105: 501-6.
9. Maschmeyer G, Link H, Hiddemann W et al. Pulmonary infiltrations in febrile patients with neutropenia: risk factors and outcome under empirical antimicrobial therapy in a randomized multicenter study. Cancer 1994; 73: 2296-304.
10. Brakhage AA. Systemic fungal infections caused by Aspergillus species: epidemiology, infection process and virulence determinants. Curr Drug Targets 2005; 6: 875-86.
11. Chaoui D, Legrand O, Roche N et al. Incidence and prognostic value of respiratory events in acute leukemia. Leukemia 2004; 18: 670-5.
12. Maschmeyer G, Beinert T, Buchheidt D et al. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients-guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2003; 82 Suppl 2: S118-26.
13. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis 2004; 39 Suppl 1: S38-43.
14. Ullmann AJ, Sanz MA, Tramarin A et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43: e29-38.
15. Walsh TJ, Teppler H, Donowitz GR et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391-402.
16. Herbrecht R, Denning DW, Patterson TF et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
17. Gahrton G, Svensson H, Cavo M et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994-8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-16.
18. Ascioglu S, Rex JH, de Pauw B et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
19. de Pauw B, Walsh TJ, Donnelly JP et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
20. Büchner T, Hiddemann W, Wörmann B et al. Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood 1999; 93: 4116-24.
21. Schlenk RF, Fröhling S, Hartmann F et al. Phase III study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia. Leukemia 2004; 18: 1798-803.
22. Glasmacher A, Hahn C, Molitor E et al. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-(-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999; 42: 591-600.
23. Maertens J, Verhaegen J, Lagrou K et al. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001; 97: 1604-10.
24. Reinicke A, Scheer C, Häfner J et al. Rapid diagnostics of aspergillosis from bronchoalveolar lavage samples using realtime-PCR. In: Abstracts of the Forty-first Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2001. Abstract J-843, p. 386. American Society for Microbiology, Washington, DC, USA.
25. Upton A, Kirby KA, Carpenter P et al. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007; 44: 531-40.
26. Nivoix Y, Velten M, Letscher-Bru V et al. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47: 1176-84.
27. Martino R, Subira M, Rovira M et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-82.
28. Kobayashi R, Kaneda M, Sato T et al. The clinical feature of invasive fungal infection in pediatric patients with hematologic and malignant diseases: a 10-year analysis at a single institution at Japan. J Pediatr Hematol Oncol 2008; 30: 886-90.
29. Metcalf SC, Dockrell DH. Improved outcomes associated with advances in therapy for invasive fungal infections in immunocompromised hosts. J Infect 2007; 55: 287-99.
30. Post MJ, Lass-Floerl C, Gastl G et al. Invasive fungal infections in allogeneic and autologous stem cell transplant recipients: a single-center study of 166 transplanted patients. Transpl Infect Dis 2007; 9: 189-95.
31. Hachem R, Hanna H, Kontoyiannis D et al. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 2008; 112: 2493-9.